[Federal Register Volume 59, Number 9 (Thursday, January 13, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-849]


[[Page Unknown]]

[Federal Register: January 13, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Opportunity for a License for Nonpatented Material

AGENCY: Centers for Disease Control and Prevention (CDC), Public Health 
Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), National 
Center for Infectious Diseases (NCID), Division of Viral and 
Rickettsial Diseases (DVRD), Hepatitis Branch, has available for 
licensing recombinant proteins and synthetic peptides containing 
broadly immunoreactive antigenic epitopes to be used as 
immunodiagnostic reagents for the detection of antibodies to the 
Hepatitis C Virus (HCV).

FOR FURTHER INFORMATION CONTACT: If you are interested in the 
opportunity for a license to the nonpatented material described above, 
please contact the following for additional information.
    Technical Contact: Howard A. Fields, Ph.D., Division of Viral and 
Rickettsial Diseases, Centers for Disease Control and Prevention (CDC), 
1600 Clifton Road, NE., Mailstop A-33, Atlanta, GA 30333, telephone 
404-639-2335.
    Business Contact: Lisa Blake-Dispigna, Technology Transfer 
Representative, National Center for Infectious Diseases, Centers for 
Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Mailstop 
C-19, Atlanta, GA 30333, telephone 404-639-3227.

SUPPLEMENTARY INFORMATION: A set of recombinant glutathione-S-
transferase fusion proteins have been prepared by using polymerase 
chain reaction to amplify the NS3-NS4-NS5 region of the hepatitis C 
virus (HCV) genome in 300 (monomers) and 600 (dimers) nucleotide 
fragments. Most of the monomers and dimers have been expressed in 
Escherichia coli and tested against a panel of anti-HCV positive and 
negative sera to ascertain specificity. A full length authentic 
fusionless recombinant nucleocapsid protein has also been prepared and 
tested as an immunodiagnostic reagent. This single protein alone will 
detect approximately 90% of anti-HCV positive sera. Synthetic peptides 
have been prepared to the nucleocapsid region in addition to the NS3-
NS4-NS5 region. All the synthetic peptides have been tested to 
determine their immunoreactivity.
    The nonpatented recombinant proteins and synthetic peptides are now 
available for licensing, and if interested, see FOR FURTHER INFORMATION 
CONTACT section of notice.

    Dated: January 6, 1994.
Ladene H. Newton,
Acting Associate Director for Management and Operations, Centers for 
Disease Control and Prevention (CDC).
[FR Doc. 94-849 Filed 1-12-94; 8:45 am]
BILLING CODE 4160-18-P